What is Panobinostat?
Panobinostat is an oral anticancer agent being developed by Novartis that inhibits multiple enzymes that cancer cells need to grow and survive. It is known as a deacetylase (DAC) inhibitor, and is also known by the name LBH589. Panobinostat also inhibits the growth of new blood vessels needed for tumors to grow. Panobinostat is being studied in myeloma as well as other blood cancers and solid tumors.
The Multiple Myeloma Research Consortium (MMRC) has played a role in this drug’s development and is currently facilitating trials evaluating Panobinostat in combination with another myeloma agent.